Xilio Development Inc

Stock Chart, Company Information, and Scan Results

$0.73(as of Dec 5, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Xilio Development Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$0.73
Ticker SymbolXLO
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees64
CountyUSA
Market Cap$38.3M

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Development Inc In Our Stock Scanner

As of Dec 08, 2025
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.